NCT00001934View on ClinicalTrials.gov

Zenapax to Treat Multiple Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

September 30, 1999

Primary Completion Date

August 31, 2005

Study Completion Date

September 30, 2008

Conditions
Multiple Sclerosis
Interventions
DRUG

Zenapax

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

NCT00001934 - Zenapax to Treat Multiple Sclerosis | Biotech Hunter | Biotech Hunter